// App-Quantinova.ai

8039 : Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.

Researchers

Presenter

  • Maria-Victoria Mateos

Principal Investigators

  • Tamas Masszi

  • Norbert Grzasko

  • Markus Hansson

  • Irwindeep Sandhu

  • Ludek Pour

  • Luisa Viterbo

  • Sharon R. Jackson

  • Anne-Marie Stoppa

  • Peter Gimsing

  • Mehdi Hamadani

  • Gabriela Borsaru

  • Deborah Berg

  • Jianchang Lin

  • Helgi Van De Velde

  • Paul G. Richardson

  • Philippe Moreau

Medical Centers

  • Servicio de Hematologia, Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain

  • Fovarosi Onkormanyzat Szent Laszlo Korhaza, Hematologia, Budapest, Hungary

  • Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, and St John's Cancer Center, Lublin, Poland

  • Department of Hematology, Skane University Hospital, Lund University, Lund, Sweden

  • Department of Medicine, Division of Hematology, University of Alberta, Edmonton, AB, Canada

  • Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

  • Servico de Onco-Hematologia, Instituto Portugues de Oncologia do Porto Francisco Gentil, Entidade Publica Empresarial (IPOPFG, EPE), Porto, Portugal

  • Department of Haematology, Middlemore Hospital, Auckland, New Zealand

  • Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France

  • Department of Hematology, University Hospital Rigshospitalet, Copenhagen, Denmark

  • The Medical College of Wisconsin, Milwaukee, WI

  • Spitalul Clinic Coltea, Hematologie, Bucarest, Romania

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Dana-Farber Cancer Institute, Boston, MA

  • University Hospital Hotel-Dieu, Nantes, France

Locations

  • Canada

  • Czech Republic

  • Romania

  • Poland

  • Spain

  • United States

  • Portugal

  • France

  • Denmark

  • Sweden

  • New Zealand

  • Hungary

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Ixazomib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT01564537

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved